首页 | 本学科首页   官方微博 | 高级检索  
检索        

肝细胞癌(HCC)对索拉非尼耐药相关机制的研究进展
引用本文:胡倍源.肝细胞癌(HCC)对索拉非尼耐药相关机制的研究进展[J].复旦学报(医学版),2018,45(6):884.
作者姓名:胡倍源
作者单位:(1复旦大学附属华山医院普外科 上海 200040; 2复旦大学生物医学研究院 上海 200032; 3复旦大学肿瘤转移研究所 上海 200040)
基金项目:国家自然科学基金(81372647, 81672820, 81772563); 十二五科技部重大专项计划(2012XZ10002012)
摘    要: 肝细胞癌(hepatocellular carcinoma, HCC)是常见的恶性肿瘤之一。分子靶向药物索拉非尼是不能手术切除的进展期HCC的一线疗法。但部分HCC对其耐药性的出现影响了总体疗效,耐药可分为原发性(HCC原本就对索拉非尼缺乏敏感性)和获得性(开始敏感,治疗过程中出现耐药)两类,其机制尚不清楚。HCC对索拉菲尼的耐药机制主要表现在肝癌细胞自身和肿瘤微环境两个方面:前者包括细胞自噬、上皮-间质转化(epithelial-mesenchymal transition, EMT)、铁死亡(ferroptosis)受抑制和肿瘤起始细胞(tumor-initiating cell, T-IC)等;后者包括外泌体(exosome)和血管选定等。本文对其相关研究进展进行总结。

关 键 词:细胞表型  自噬  上皮-间质转化(EMT)  铁死亡  肿瘤起始细胞(T-IC)  外泌体  血管选定  索拉非尼
收稿时间:2017-10-25

Progress in the mechanism studies of hepatocellular carcinoma (HCC) resistance to sorafenib treatment
HU Bei-yuan,QIN Wei,DONG Qiong-zhu,QIN Lun-xiu,.Progress in the mechanism studies of hepatocellular carcinoma (HCC) resistance to sorafenib treatment[J].Fudan University Journal of Medical Sciences,2018,45(6):884.
Authors:HU Bei-yuan  QIN Wei  DONG Qiong-zhu  QIN Lun-xiu    
Institution:(1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China; 2Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China; 3Cancer Metastasis Institute, Fudan University, Shanghai 200040, China)
Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers all over the world. Sorafenib is the only first line proved treatment for advanced HCC patients. However, the emergence of sorafenib resistance impacts on the efficacy of HCC treatment, which can be primary or acquired (primary sensitive, and resistant late during treatment process). At present, the mechanism of sorafenib resistance is not clear yet, which can be related to the aberrations in genetics and phenotype of HCC cells and the modifications in tumor microenvironment. The autophagy, epithelial-mesenchymal transition (EMT), ferroptosis, and tumor-initiating cells (T-ICs) phenotype of HCC cells, as well as exosomes and vessel co-option, have drawn much attentions in recent years. We summarized the progress of the related studies in this article.
Keywords:phenotype  autophagy  epithelial-mesenchymal transition (EMT)  ferroptosis  tumor-initiating cell (T-IC)  exosomes  vessel co-option  sorafenib
点击此处可从《复旦学报(医学版)》浏览原始摘要信息
点击此处可从《复旦学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号